WHAT AND WHY?
HOW AND WITH WHOM?
RESULTS, IMPACT AND RECOMMENDATIONS
What next?
Needle-free
diabetes management
Fast interstitial fluid sampling for non-invasive diabetes management
Dr. Alejandro García Pérez, PhD.
• Over 400 MILLION people suffer from diabetes.
• Over 1.9 BILLION people are overweight (at risk of getting diabetes).
• Our technology promotes better management and prevention of
diabetes by enabling convenient, non-invasive and painless glucose
monitoring.
We developed a patent pending solution to extract interstitial fluid from the
dermis in a painless and non-invasive manner. The concentration of
glucose in interstitial fluid is measured using state-of-the-art biosensors,
and it correlates with blood glucose.
Key collaborators and stakeholders: University of Helsinki, Åbo Akademi
University, Business Finland, and IoT Forge Foundation. The project
involved top experts from Finland, México, Russia and Canada.
Results from a pilot study in healthy individuals showed that our technology meets the level of analytical accuracy required for regulatory clearance.
This project has created a compelling foundation to establish GlucoModicum Oy (Y-tunnus: 2900506-7).
Public Relations & Eco-system engagement with high impact audiences.
Finalize the prototype
Start early-phase clinical trials
Apply for regulatory clearance
Continue engagement with technology and pharma companies
• Patent pending technology for extraction of dermal interstitial fluid
is tested in humans.
• Initial prototype built. We demonstrated that the solution can be
implemented into a small formfactor.
• Final solution encompasses our novel interstitial fluid sampling
method, state-of-the-art biosensors and a convenient user
interface.
Figure 1. Key achievements
More information:
Alejandro García Pérez
Partners:
From academic research to scientific and societal impact
